BlackRock Inc. Grows Position in Zoetis Inc. $ZTS

BlackRock Inc. raised its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 10.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 39,430,181 shares of the company's stock after purchasing an additional 3,845,869 shares during the quarter. BlackRock Inc. owned 9.41% of Zoetis worth $2,833,453,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. University of Texas Texas AM Investment Management Co. bought a new position in Zoetis in the 2nd quarter worth about $25,000. Dunhill Financial LLC lifted its stake in Zoetis by 519.3% in the second quarter. Dunhill Financial LLC now owns 353 shares of the company's stock worth $25,000 after acquiring an additional 296 shares during the period. Prosperity Bancshares Inc bought a new position in Zoetis during the 4th quarter worth about $25,000. Cassaday & Co Wealth Management LLC purchased a new position in Zoetis during the 1st quarter valued at about $28,000. Finally, Root Financial Partners LLC raised its holdings in shares of Zoetis by 66.5% in the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company's stock valued at $30,000 after purchasing an additional 103 shares in the last quarter. Institutional investors own 92.80% of the company's stock.

Zoetis Trading Up 1.5%

Zoetis stock opened at $74.04 on Wednesday. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. Zoetis Inc. has a 52 week low of $71.00 and a 52 week high of $160.48. The company has a market capitalization of $30.60 billion, a price-to-earnings ratio of 12.20, a price-to-earnings-growth ratio of 1.28 and a beta of 0.73. The stock has a 50-day moving average price of $76.01 and a 200 day moving average price of $98.13.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping analysts' consensus estimates of $1.85 by $0.02. The firm had revenue of $2.47 billion for the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The company's revenue was down .2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Sell-side analysts anticipate that Zoetis Inc. will post 6.2 EPS for the current year.

Wall Street Analyst Weigh In

ZTS has been the subject of several research reports. HSBC lowered their price target on shares of Zoetis from $140.00 to $95.00 and set a "buy" rating for the company in a research report on Monday, July 6th. Citigroup reduced their price objective on shares of Zoetis from $112.00 to $96.00 and set a "buy" rating for the company in a research note on Tuesday, August 11th. TD Cowen lowered their target price on Zoetis from $150.00 to $104.00 and set a "buy" rating for the company in a report on Tuesday, June 30th. William Blair reiterated a "market perform" rating on shares of Zoetis in a report on Thursday, August 6th. Finally, Barclays decreased their price objective on Zoetis from $136.00 to $85.00 and set an "equal weight" rating for the company in a research note on Wednesday, July 1st. Eight equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $109.62.

Zoetis Company Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source